J&J launches second PhIII COVID-19 trial
Janssen will enrol participants in countries with high incidence of COVID-19, including the UK
Read More
Tag: J&J
UCLB, Apollo secure first licensing deal with US investment powerhouse
Deerfield is partnering on the development of a novel gene therapy
Read More
J&J announce first-of-its-kind portopulmonary hypertension study results
The findings “Provide important clinical evidence to help inform treatment decisions and fill an unmet need that should benefit patients living with PoPH.”
Read More
Plaque psoriasis study claims Tremfya superior to Cosentyx
Janssen’s plaque psoriasis treatment Tremfya was found to be superior to Novartis’ Cosentyx in treating adults with moderate-to-severe cases of the condition, according to findings of a late-stage study.
Read More
GSK retains leading position on access to medicines list
GlaxoSmithKline has retained its top position among a global list of pharmaceutical companies striving to make their medicines, vaccines and diagnostics more accessible for people in low- and middle-income countries.
Read More
US expands scope of J&J’s biologic Stelara in psoriasis
US regulators have approved an expansion of Johnson & Johnson’s Stelara to include younger patients with plaque psoriasis.
Read More
J&J ordered to pay $417m fine in cancer talc case
Johnson & Johnson has been ordered by a jury in California to pay $417 million to a woman who claims to have developed ovarian cancer from regular use of its talc-based products.
Read More
EU clears J&J’s Actelion buy, with conditions
The European Commission has issued a conditional green light for Johnson & Johnson’s planned $30 billion purchase of Actelion, laying out the commitments it feels are necessary to ensure that clinical development of the firms’ innovative insomnia drugs will not be adversely affected by the merger.
Read More
J&J shells out $30 billion on Actelion
Johnson & Johnson and Actelion have announced a $30 billion merger that will see the latter’s R&D unit spun out into a separate business, ending months of speculation.
Read More
AZ sells Rhinocoart Aqua rights to Cilag
AstraZeneca has completed the sale of rights to nasal spray Rhinocort Aqua to Johnson & Johnson group Cilag GmbH.
Read More
J&J’s Stelara wins US nod for Crohn’s
US regulators have expanded the reach of Johnson & Johnson group Janssen Biologics’ psoriasis blockbuster Stelara to include the treatment of patients with Crohn’s disease.
Read More
Janssen licenses DART molecule from MacroGenics
Johnson & Johnson group Janssen has signed a deal with US biopharma MacroGenics for a license to its preclinical bispecific molecule MGD015.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
